Stockscreener 앱 받기
0.7883
14.25%
0.0983
시장 영업 전:
.80
0.0117
+1.48%
전일 마감가:
$0.69
열려 있는:
$0.7
하루 거래량:
6.19M
Relative Volume:
1.32
시가총액:
$284.96M
수익:
$1.21M
순이익/손실:
$-177.12M
주가수익비율:
-0.9854
EPS:
-0.8
순현금흐름:
$-162.37M
1주 성능:
+13.93%
1개월 성능:
+10.30%
6개월 성능:
-60.39%
1년 성능:
-39.36%
1일 변동 폭
$0.6801
$0.8099
1주일 범위
$0.6738
$0.8099
52주 변동 폭
$0.6204
$3.73
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
LXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
0.7883 | 284.96M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - NRToday.com
Lexicon Pharma to Host Expert Panel on Groundbreaking Non-Opioid Pain Treatment LX9211 - StockTitan
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Lexicon Pharmaceuticals faces potential Nasdaq delisting - Investing.com India
Lexicon Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com Nigeria
Strong week for Lexicon Pharmaceuticals (NASDAQ:LXRX) shareholders doesn't alleviate pain of five-year loss - Simply Wall St
Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Lexicon Pharmaceuticals, Inc. Appoints Scott M. Coiante as Senior Vice President - Marketscreener.com
Lexicon Pharmaceuticals, Inc. Announces CFO Changes - Marketscreener.com
Lexicon Pharmaceuticals, Inc. Appoints Scott Coiante as Senior Vice President - Marketscreener.com
Lexicon Appoints Scott Coiante as Chief Financial Officer - The Manila Times
Lexicon Pharmaceuticals Names Scott Coiante Finance Chief - MarketWatch
Lexicon Pharma (LXRX) Appoints Scott Coiante as CFO - StreetInsider.com
Lexicon Pharmaceuticals Names Veteran Pharma Executive Scott Coiante as New CFO - StockTitan
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Cor - AccessWire
Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33% - Yahoo Finance
Lexicon Zynquista vista narrows with diabetes CRL; gain due in pain? - BioWorld Online
Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Analyst Expectations For Lexicon Pharmaceuticals's Future - Benzinga
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - The Manila Times
Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista? (sotagliflozin) - Marketscreener.com
Stocks to Watch: Rumble, Lexicon Pharmaceuticals - MarketWatch
FDA rejects Lexicon's Zynquista for diabetes, kidney disease - Seeking Alpha
US FDA declines to approve Lexicon Pharma's add-on diabetes drug - Reuters
Lexicon Pharma Receives FDA Rejection for Diabetes Drug Zynquista, Shifts Focus to Pain Treatment Pipeline - StockTitan
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Sector Weakness - GuruFocus.com
Hypertrophic Cardiomyopathy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Edgewise Therapeutics, Novartis, Lexicon Pharma, Shandong Suncadia Medicine, Ji Xing Pharma - Barchart
Point72 Asset Management L.P. Sells 2,891,141 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer - Business Wire
Fmr LLC Has $78.29 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals (LXRX) Stock Dips Amid Market Volatility - GuruFocus.com
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 - Investing.com India
Biotech Stocks Facing FDA Decision In December 2024 - RTTNews
Braidwell LP Sells 7,493,366 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon completes subject enrolment for DPNP trial of LX9211 - Clinical Trials Arena
2 Generic Drug Stocks Ready to Surge in 2025 - Benzinga
The Escalator: Lexicon Pharmaceuticals, Reckitt, NIH and more - MM+M Online
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - The Manila Times
Lexicon Pharma Hits 120% Enrollment Target in Key Pain Drug Trial, Ahead of Schedule | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals to Participate in December Investor Conferences - The Manila Times
Lexicon Pharmaceuticals CEO to Present at Two Major Healthcare Conferences in December | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals shares target cut, retains buy rating on FDA letter - Investing.com UK
Lexicon pivots back to pipeline after FDA rejection - The Pharma Letter
Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Hold" Rating from Needham & Company LLC - MarketBeat
Lexicon Pharmaceuticals to cut 60% of workforce By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals to cut 60% of workforce - Investing.com India
Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown - Citeline News & Insights
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):